Advertisement

Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults

Published:December 17, 2018DOI:https://doi.org/10.1016/j.amepre.2018.09.020

      Introduction

      Neisseria meningitidis serogroup B is the most common form of meningococcal infection in young adults in the U.S. Vaccines have recently become available, but it is not clear that the benefits outweigh the costs. The purpose of this study was to assess cost effectiveness and determine potentially favorable conditions for universal vaccination.

      Methods

      Costs and benefits of universal vaccination at college entry versus no universal vaccination with an outbreak response were estimated in 2018 in the context of a mid-sized U.S.-based 4-year college from both a health sector and a societal perspective. Probability, cost, and utility data were obtained from the published literature. Costs (2015 U.S.$) and benefits were discounted at 3%. One-way and multivariable probabilistic sensitivity analyses were performed including variations in the specific vaccine used. Further testing of the model's parameters at extremes was used to identify favorable conditions for universal vaccination.

      Results

      The incremental cost per quality-adjusted life year gained with universal vaccination was $13.9 million under the health sector perspective and $13.8 million under the societal perspective, each perspective was compared with a willingness-to-pay threshold of $150,000 per quality-adjusted life year. Multivariable probabilistic sensitivity analysis showed that universal vaccination was not the preferred strategy for <$15 million per quality-adjusted life year. Under an extremely favorable model, a universal vaccination strategy became cost effective for vaccine series costing <$65.

      Conclusions

      This study demonstrates that universal vaccination at college entry is not cost effective. The rarity of N. meningitidis serogroup B contributes to the lack of cost effectiveness for universal vaccination.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Rosenstein NE
        • Perkins BA
        • Stephens DS
        • Popovic T
        • Hughes JM
        Meningococcal disease.
        N Engl J Med. 2001; 344: 1378-1388
        • Stephens DS
        • Greenwood B
        • Brandtzaeg P
        Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.
        Lancet. 2007; 369: 2196-2210
      1. Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf. Published 2016. Accessed April 23, 2018.

        • Soeters HM
        • Dinitz-Sklar J
        • Kulkarni PA
        • et al.
        Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016.
        Emerg Infect Dis. 2017; 23: 867-869
      2. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for use of serogroup B meningococcal (MenB) vaccines in persons at increased risk for serogroup B meningococcal disease. www.cdc.gov/vaccines/acip/recs/grade/mening-serogroup-b.html. Published 2015. Accessed April 24, 2018.

        • Patton ME
        • Stephens D
        • Moore K
        • MacNeil JR
        Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—Advisory Committee on Immunization Practices, 2016.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 509-513
      3. Centers for Disease Control and Prevention (CDC). Vaccines for Children Program. www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html. Published 2018. Accessed March 15, 2018.

      4. National Meningitis Association. Beyond the Science: Putting a Face on Meningococcal Disease. Fort Meyers, FL; National Meningitis Association. www.nmaus.org/wp-content/uploads/2015/02/nma-beyond-the-science-report.pdf. Published 2015. Accessed September 27, 2018.

      5. Herzog K. Separate vaccine can protect against meningitis B strain. USA Today. http://college.usatoday.com/2016/08/17/separate-vaccine-can-protect-against-meningitis-b-strain/. Published August 17, 2016. Accessed September 27, 2018.

        • Sanders GD
        • Neumann PJ
        • Basu A
        • et al.
        Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses.
        JAMA. 2016; 316: 1093-1103
        • Neumann PJ
        • Sanders GD
        • Russell LB
        • Siegel JE
        • Ganiats TG
        Cost-Effectiveness in Health and Medicine.
        2nd ed. Oxford University Press, New York, NY2017
      6. Centers for Disease Control and Prevention (CDC). Guidance for the Evaluation and Public Health Management of Suspected Outbreak of Meningococcal Disease. Atlanta, GA: CDC. www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf. Published 2017. Accessed September 27, 2018.

      7. Social Security Administration. Actuarial life table. www.ssa.gov/oact/STATS/table4c6.html. Published 2014. Accessed April 6, 2018.

        • Parikh SR
        • Andrews NJ
        • Beebeejaun K
        • et al.
        Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
        Lancet. 2016; 388: 2775-2782
        • Parikh SR
        • Newbold L
        • Slater S
        • et al.
        Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and quantitative assessment.
        Lancet Infect Dis. 2017; 17: 754-762
        • Granoff DM
        Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
        Pediatr Infect Dis J. 2013; 32: 372-373
        • Stein-Zamir C
        • Shoob H
        • Sokolov I
        • Kunbar A
        • Abramson N
        • Zimmerman D
        The clinical features and long-term sequelae of invasive meningococcal disease in children.
        Pediatr Infect Dis J. 2014; 33: 777-779
        • Pace D
        • Pollard AJ
        Meningococcal disease: clinical presentation and sequelae.
        Vaccine. 2012; 30: B3-B9
        • Wang B
        • Haji Ali Afzali H
        • Marshall H
        The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.
        Vaccine. 2014; 32: 4791-4798
        • Sadarangani M
        • Scheifele DW
        • Halperin SA
        • et al.
        Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study.
        Clin Infect Dis. 2015; 60: e27-e35
        • Kirsch EA
        • Barton RP
        • Kitchen L
        • Giroir BP
        Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience.
        Pediatr Infect Dis J. 1996; 15: 967-978
      8. Pfizer. STN 125549-360. PI approved final draft (Trumemba package insert). www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf. Published 2014. Accessed April 23, 2018.

      9. GlaxoSmithKline. 125546-189. PI approved final draft (Bexsero package insert). www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf. Published 2015. Accessed April 23, 2018.

        • Trotter CL
        Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
        BMJ. 2002; 324 (809–809)
      10. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project Databases. www.hcup-us.ahrq.gov/nisoverview.jsp. Published 2016. Accessed April 23, 2018.

        • Wright C
        • Wordsworth R
        • Glennie L
        Counting the cost of meningococcal disease.
        Pediatr Drugs. 2013; 15: 49-58
        • Mohr PE
        • Feldman JJ
        • Dunbar JL
        • et al.
        The societal costs of severe to profound hearing loss in the United States.
        Int J Technol Assess Health Care. 2000; 16: 1120-1135
        • MacKenzie EJ
        • Jones AS
        • Bosse MJ
        • et al.
        Health-care costs associated with amputation or reconstruction of a limb-threatening injury.
        J Bone Joint Surg Am. 2007; 89: 1685-1692
        • Liu G
        Measuring the stock of human capital for international and intertemporal comparisons.
        in: Jorgenson DW Landefeld S Schreyer P Measuring Economic Sustainability and Progress. University of Chicago Press, Chicago, IL2014: 493-544
      11. Mathers CD, Murray CJL, Lopez AD, et al. Estimates of Health Life Expectancy for 191 Countries in the Year 2000: Methods and Results. Geneva, Switzerland: WHO. www.who.int/choice/publications/d_2000_gpe38.pdf?ua=1. Published 2000. Accessed September 27, 2018.

        • Vega-Hernandez G
        • Wojcik R
        • Schlueter M
        Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK.
        Diabetes Ther. 2017; 8: 513-530
        • Cheng X
        • Zhao Y
        • Zhang X
        • Jin H
        • Min J
        Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.
        Hum Vaccin Immunother. 2017; 13: 1873-1878
        • Shiragami M
        • Mizukami A
        • Leeuwenkamp O
        • et al.
        Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children.
        Infect Dis Ther. 2014; 4: 93-112
        • Martí SG
        • Colantonio L
        • Bardach A
        • et al.
        A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.
        Cost Eff Resour Alloc. 2013; 11: 21
        • Pomeroy SL
        • Holmes SJ
        • Dodge PR
        • Feigin RD
        Seizures and other neurologic sequelae of bacterial meningitis in children.
        N Engl J Med. 1990; 323: 1651-1657
      12. European Center for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_Communicable_ Diseases_in_Europe.pdf. Published 2011. Accessed April 24, 2018.

        • Briggs A
        • Sculpher M
        • Claxton K
        Decision Modeling for Health Economic Evaluation.
        Oxford University Press, Oxford, England2006
        • Ubel PA
        • Hirth RA
        • Chernew ME
        • Fendrick AM
        What is the price of life and why doesn't it increase at the rate of inflation.
        Arch Intern Med. 2003; 163: 1637-1641
        • Marseille E
        • Larson B
        • Kazi DS
        • Kahn JG
        • Rosen S
        Thresholds for the cost-effectiveness of interventions: alternative approaches.
        Bull World Health Organ. 2015; 93: 118-124
      13. Centers for Disease Control and Prevention (CDC). Meningococcal disease. www.cdc.gov/meningococcal/surveillance/index.html. Published 2018. Accessed April 24, 2018.

        • Harrison LH
        Epidemiological profile of meningococcal disease in the United States.
        Clin Infect Dis. 2010; 50: S37-S44
        • McNeil BJ
        • Pauker SG
        • Sox HC
        • Tversky A
        On the elicitation of preferences for alternative therapies.
        N Engl J Med. 1982; 306: 1259-1262